At a time when Muhammad Yunus and his interim regime in Bangladesh face mounting uncertainty, pharma-giant Renata Limited – which emerged in 1993 after Bangladeshi owners acquired Pfizer’s local operations – has triggered a new wave of controversy that may seriously erode what remains of the administration’s credibility. The company’s failure to deliver on a crucial health supply contract has sparked suspicion of corporate sabotage, raising questions of whether Bangladesh is being pushed toward yet another foreign-engineered political upheaval. For many analysts, the unfolding crisis echoes the dramatic events of January 11, 2007, when the military intervened to impose a caretaker government amid political breakdown.

The Renata episode exposes not only the weakness of Yunus’s interim administration but also highlights the deeper role of global pharmaceutical corporations in shaping domestic politics, foreign policy, and even regime change. In the United States and Europe, it is well established that alongside the Military Industrial Enterprises, the Pharma Industrial Enterprises hold immense influence, shaping regulatory agendas, health priorities, and often foreign policy decisions. Together, these sectors provide both the funding and strategic heft of the so-called “Deep State,” wielding power far beyond the ballot box.

In May 2025, Renata signed an agreement with the Directorate General of Family Planning, under the Ministry of Health, to supply 14,750 boxes of DDS kits by September 2025. As of late August 28, 2025, however, not a single consignment had been delivered. The company cited Bangladesh’s foreign currency shortage, difficulties in opening letters of credit, and “political unrest” as reasons for non-compliance.

But these explanations lack credibility. Political protests had subsided more than a year earlier, and while........

© Blitz